Table of Contents
- Trial overview
- Who is being studied
- Trial design and phase
- What is being measured
- Study treatment plan
- Key patient terms
Trial overview
The available trial data describe one interventional study of ACICLOVIR SODIUM in people with relapsing-remitting multiple sclerosis.[1] The study is titled HiHat trial and is listed as authorised.[1]
This trial is not presented as a general drug monograph. It is specifically about a clinical research project that is testing a treatment plan and measuring safety in a defined patient group.[1]
Who is being studied
The target population is patients with relapsing-remitting multiple sclerosis and less than 10 years of disease duration.[1] This means the study focuses on people whose disease has been present for a shorter time, rather than those with long-standing disease.[1]
The trial plan includes 50 participants.[1] This is a relatively small group, which is common in early clinical research when researchers are still checking safety and early signals of benefit.[1]
Trial design and phase
The study is an interventional trial, which means the research team assigns the treatment plan rather than only observing usual care.[1] It is in Phase 2, a stage that usually looks more closely at safety and early effectiveness in a selected patient group.[1]
The brief summary says the main objective is to evaluate whether the serious adverse event rate associated with sequential treatment of rituximab followed by cladribine is acceptably low.[1] In simple terms, the study is checking whether serious medical problems linked to the treatment plan happen at a low rate.[1]
What is being measured
The primary outcome is the binary indicator of at least one treatment-related serious adverse event per participant.[1] A binary indicator is a yes-or-no result, so each participant is counted as either having had at least one such event or not.[1]
The phrase treatment-related means the researchers think the event may be connected to the study treatment.[1] The phrase serious adverse event means a serious medical problem that happens during the study.[1]
Study treatment plan
The intervention list includes ACICLOVIR, cetirizine, methylprednisolone, rituximab, cladribine, sulfamethoxazole and trimethoprim, and paracetamol.[1] The brief summary specifically links the safety question to sequential treatment with rituximab followed by cladribine.[1]
For patients, the important point is that the trial is evaluating a treatment sequence, not just one single medicine.[1] The study is asking whether this planned sequence can be given with an acceptably low rate of serious treatment-related problems.[1]
Key patient terms
Authorised means the trial has approval to proceed.[1] Enrollment means the planned number of participants who will join the study.[1]
Sequential treatment means one treatment is given after another in a set order.[1] Primary outcome means the main result the researchers want to measure.[1]
